Golden, CO, and Fort Collins, CO – GelSana, a startup helping people by developing novel hydrogels to heal wounds faster with less inflammation, has announced that they have closed their investment round of $1.35M. Leading the round was Innosphere Ventures Fund, a venture capital fund leading early-stage investments in Colorado and the Mountain Plains region of the US. GelSana will use the proceeds to bring their first wound-care product to commercial readiness.

“Innosphere Fund backs exceptional technical founders, like Founder/CEO Melissa Krebs.  We are excited to support Melissa and the Colorado School of Mines with this investment in GelSana,” says Mike Freeman, General Partner of Innosphere Ventures Fund.

“Chronic wounds suffer from high levels of inflammation which impairs the natural healing process. Wound dressings currently available do not address the inflammation problem and are also not capable of sustained therapeutic delivery,” Says CEO and founder of GelSana, Melissa Krebs, Ph.D.

GelSana’s novel hydrogel technology helps reduce inflammation at the wound site, decreasing healing time. Faster healing minimizes the risk of infection and amputation, making the solution particularly effective for diabetic foot ulcers. GelSana’s novel hydrogels have superior handling properties. The hydrogels can also provide sustained release of therapeutics to the wound bed over time, promoting even faster healing.

“Working with Innosphere to strategically build and scale our company has been game-changing,” said Dr Krebs. “The knowledge and support I received through Innosphere’s incubation program and then through the Innosphere Ventures Fund have been invaluable.”

GelSana was recently awarded “Most Innovative Emerging Wound Care Product Company 2022,” by the Global Health & Pharma group at the annual Biotechnology Awards. https://www.ghp-news.com/winners/gelsana-therapeutics/

For more information on Innosphere Ventures and this investment, contact Mike Freeman, General Partner of Innosphere Ventures Fund, at [email protected].